Watch this Weeks Episode Saturday at 9am CT
State of the Art: Harnessing the Power of PARP Inhibitors to Improve Outcomes for Eligible Patients with Metastatic Prostate Cancer in VHA and Community Health Care Systems
CME | CNE | CPE | 1.0 Credit
Click for Credit
This program will prepare clinicians with a comprehensive understanding of the appropriate treatment of patients with mPC and the clinical utility of agents that could significantly impact patient outcomes. PARP inhibitors, which are one of the most promising new classes of agents for mPC, offer the potential for better survival for eligible patients. This program will educate clinicians on how to address the challenges of integrating these agents into practice as well as review the latest evidence on genetic testing to identify eligible patients, methods for personalizing therapy, the indications for PARP inhibitor-based monotherapy and combination therapy for mPC, earlier use of PARPi in the course of disease, and how to manage adverse events. After completing this program, clinicians will be prepared with a thorough knowledge of the current landscape and the applications of PARP inhibitors within the health care system.
*The expert's opinions in this communication are personal and not representative of any organization. They are for informational purposes only, not official guidance. Viewers are advised to use their judgment, seek additional advice, and take responsibility for any actions based on these opinions.
Click on image to visit our sponsor's website.
Click below for sponsorship info.
Episode 216: Immunotherapy in Bladder Cancer: Practice-Changing Advances Every Urology Professional Should Know
CME | CNE |1.00 Credit
Episode 201: Unraveling the Complexities of cUTI Care: Modernizing cUTI Care with the 2025 IDSA and EAU Updates
CME | CNE | CPE | 1.00 CreditEpisode 196: Opportunistic Pathogens in Healthcare: Hidden Threats Every Nurse Must Know
Click for Contact HoursEpisode 184: Optimizing Urothelial Carcinoma Therapy: From Maintenance to Precision Strategies
1.00 / CME Contact Hour183: Optimizing Care in Advanced Renal Cell Carcinoma: Immunotherapy & Targeted Agents Explained
1.00 / ANCC Contact Hour179: The Future of Prostate Cancer Care: New Treatments Explained for Urology Nurses
1.00 / ANCC Contact HourThe information provided on the site is for educational purposes only, and does not substitute for professional medical advice.
Consult a medical professional or healthcare provider if you are seeking medical advice, diagnoses, or treatment.